Logo - springer
Slogan - springer

Biomedical Sciences - Pharmacology & Toxicology | AAPS PharmSciTech (Editorial Board)

AAPS PharmSciTech

AAPS PharmSciTech

An Official Journal of the American Association of Pharmaceutical Scientists

Editor-in-Chief: Robert O. Williams III

ISSN: 1530-9932 (electronic version)

Journal no. 12249

$99.00 Personal Rate e-only for the Americas
Get Subscription

Online subscription, valid from January through December of current calendar year

Immediate access to this year's issues via SpringerLink

Volume(-s) with issue(-s) per annual subscription

Automatic annual renewal

More information: >> FAQs // >> Policy


Robert O. Williams, University of Texas at Austin, Austin, Texas, USA


Sanyog Jain, National Institute of Pharmaceutical Education and Research, Department of Pharmaceutics, Punjab, India;

Paul Myrdal, University of Arizona, College of Pharmacy, Tucson, Arizona, USA;

Michael Repka, University of Mississippi, School of Pharmacy, Oxford, Mississippi USA;

Claudio Salomon, National University of Rosario, Pharmacy Department, Rosario, Argentina;

Chuanbin Wu, Sun Yat-sen University, School of Pharmaceutical Sciences, Guangdong, China;

Editorial Advisory Board:

António J. Almeida, Ph.D., Universidade de Lisboa, Lisboa, Portugal;

Gavin Andrews, Queens University, School of Pharmacy, Belfast, Ireland;

Abdul Bassit, University College London School of Pharmacy, London;

Prakash Bhagav, Food and Drug Administration, Silver Spring, Maryland, USA

Robin Bogner, Department of Pharmaceutical Science, University of Connecticut, Storrs, Connecticut, USA;

Francesca Buttini, Department of Pharmacy, University of Parma, Parma, Italy;

Stephen R. Byrn, Purdue University, West Lafayette, Indiana, USA;

Carla Caramella, University of Pavia, Pavia, Italy;

Mahavir B. Chougule, College of Pharmacy, University of Hawaii at Hilo, Hawaii, USA;

Masato Yasuhara, Tokyo Medical and Dental University, Tokyo, Japan

Gaia Colombo, School of Pharmacy, University of Ferrara, Ferrara, Italy

Paolo Colombo, University of Parma, Parma, Italy;

Tansel Comoglu, Ankara University, Faculty of Pharmacy, Ankara, Turkey;

Melgardt M. De Villiers, University of Wisconsin, Madison, Wisconsin, USA;

James C. DiNunzio, Merck & Co., Inc., Kenilworth, New Jersey, USA;

Linda Felton, Department of Pharmaceutical Sciences, University of New Mexico, New Mexico, USA;

Paul Heng, Department of Pharmacy, National University of Singapore, Singapore;

Anthony J. Hickey, University of North Carolina, Chapel Hill, North Carolina USA;

Mansoor Khan, Food and Drug Administration, Silver Spring, Maryland, USA;

Peter Kleinebudde, Heinrich Heine University, Düsseldorf, Germany;

Alf Lamprecht, University of Bonn, School of Pharmacy, Bonn, Germany;

Prashanth Manda, Division of Bioequivalence, Food and Drug Administration, Silver Spring, Maryland, USA;

Dave A. Miller, Pharmaceutical and Analytical Research and Development Department, Hoffmann-La Roche, Nutley, New Jersey, USA;

Javier Morales, School of Chemical and Pharmaceutical Sciences, University of Chile, Chile;

S. Narasimha Murthy, University of Mississippi School of Pharmacy, Mississippi, USA;

Wasfy Obeidat, Jordan University of Science and Technology, Jordan;

Eun-Seok Park, Sungkyunkwan University, Seoul, South Korea;

Viness Pillay, Department of Pharmacy and Pharmacology, University of the Witwatersrand, Johannesburg, South Africa;

Stuart Porter, Ashland Specialty Ingredients (ASI), Parlin, New Jersey, USA;

Thomas Rades, Department of Pharmacy, University of Copenhagen, Copenhagen;

Jay Babu Ramapuram, Harrison School of Pharmacy, Auburn University, Auburn Alabama, USA;

Alessandra Rossi, School of Pharmacy, University of Parma, Parma, Italy;

Juergen Siepmann, University of Lille, Lille, France;

Socrates Tabosa do Egito, Departamento de Farmacia, Universidade Federal do Rio Grande do Norte, Brazil;

Wei Wu, Fudan University School of Pharmacy, Shanghai, China;

Paul Young, Sydney Medical School, University of Sydney, Sydney, Australia;

Meet the Editor-in-Chief and Associate Editors 

Meet the Editor-in-Chief and Associate Editors

Robert O. (Bill) Williams III, Ph.D.- EDITOR-IN-CHIEF 

Robert O. (Bill) Williams III, Ph.D.
Bill Williams is the Johnson & Johnson Centennial Chair of Pharmaceutics and the Division Head of Pharmaceutics at the College of Pharmacy, University of Texas at Austin. He earned a B.S. in biology from Texas A & M University, a B.S. in pharmacy from the University of Texas at Austin, and a Ph.D. in pharmaceutics in 1986 from the University of Texas at Austin. Williams worked 9 years in the pharmaceutical industry in the United States and France before returning to the University of Texas at Austin in 1995.
He was elected a Fellow of the American Association of Pharmaceutical Scientists in 2006 and a Fellow of the American Institute of Medical and Biological Engineering in 2008. Williams is a member of the American Association of Pharmaceutical Scientists since its inception, as well as other professional societies, including the American Association of Colleges of Pharmacy. He is the cofounder of several companies.
Williams’ research interests include development of novel drug delivery systems for oral, pulmonary, nasal, injectable, buccal, and topical applications; development of novel particle engineering technologies for low molecular weight drugs, peptides, and proteins; and analytical technologies to characterize actives, excipients, and polymers. He has published over 350 peer-reviewed research articles, reviews, abstracts, and book chapters, and coedited two books in the fields of pharmaceutical technology and drug delivery. He is an inventor on numerous patents and patent applications. Williams served as editor-in-chief of the research journal Drug Development and Industrial Pharmacy from 2000 to 2014, and is the current editor-in-chief of AAPS PharmSciTech. He serves as a reviewer for numerous other journals.

Sanyog Jain, Ph.D .- ASSOCIATE EDITOR 

Sanyog Jain obtained his M.Pharm. and Ph.D. in pharmaceutics from Dr. Hari Singh Gour University, SAGAR (MP), India, and currently works as an associate professor at the Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics of the National Institute of Pharmaceutical Education and Research (NIPER), Mohali (Punjab), India. Previously, he worked as a scientist at the Defence Research and Development Organization (DRDO), Ministry of Defence, Government of India.
Jain’s key research interest includes exploring different types of nano drug delivery systems for various biomedical applications including targeted anticancer drug delivery; oral delivery of vaccines, peptides, and therapeutics; coencapsulation of high-dose drugs, especially antioxidants; topical and transdermal drug delivery; gene delivery; and carbon nanotubes. He has patented several nanotechnology-based drug delivery platforms and licensed Tamoxifen-SEDDS Technology for improved breast cancer therapy to the industry for commercialization.
He has authored 7 book chapters and published over 100 research papers in high-impact international journals. Jain has won several prestigious awards, including the Bharat Jyoti (The Glory of India) Award, Rising Suns in Asia Award, Alkyl Amine Young Scientist Award, INSA Medal for young scientists, OPPI Young Scientist Award, and Punjab State Young Scientist Award for outstanding research in the field of novel and improved drug delivery systems. He has supervised numerous postdoc, doctorate, and master’s level project works. Jain is a widely travelled scientist and delivered invited talks at numerous prestigious platforms. His research group has also been well funded (>2 million USD) by various government agencies and pharmaceutical industries.

Paul Myrdal, Ph.D. - ASSOCIATE EDITOR 

Gunar Myrdal
Dr. Myrdal is an Associate Professor of Pharmaceutics at the University of Arizona. He received his B.S. in Molecular and Cellular Biology (1989) and his Ph.D. in Physical Pharmaceutical Chemistry from the University of Arizona (1994). Dr. Myrdal joined the University of Arizona, College of Pharmacy during the fall of 2000. Prior to his faculty appointment, Dr. Myrdal worked for Minnesota Mining and Manufacturing (3M) in the Drug Delivery Systems Division. At 3M he interfaced directly with drug discover and provided preformulation and formulation support for preclinical and clinical studies.
Dr. Myrdal’s research laboratory is centered on drug delivery with an emphasis on parenteral, aerosol and topical drug delivery. He is the director of a drug development core for a NCI program project grant that is developing topical agents for the chemoprevention of skin cancer. Dr. Myrdal has publications on a variety of aspects of preformulation, formulation and drug delivery. He is currently an expert committee member (excipients) for the United States Pharmacopoeia (USP), and is an associate editor for American Association Pharmaceutical Scientists PharmSciTech journal

Michael A. Repka, Ph.D. - ASSOCIATE EDITOR 

Michael A. Repka is Chair and Professor of the Department of Pharmaceutics at The University of Mississippi, as well as Director of the Center for Pharmaceutical Technology. Dr. Repka joined the faculty at Ole Miss after receiving his Ph.D. from The University of Texas College of Pharmacy and founded a pharmaceutical research/development company that specializes in drug delivery.
His research interests include oral transmucosal and transdermal/trans-nail delivery systems, as well as other novel dosage forms. Many of these systems are directed toward the solubilization and delivery of poorly-soluble bioactives via Hot-Melt Extrusion (HME) Technology, which is a primary focus of his research. Dr. Repka's publications include over 70 peer-reviewed journal articles and book chapters and well over 250 presentations at national/international scientific meetings.
Dr. Repka serves on the Editorial Advisory Boards of six prestigious journals and has been credentialed as a member to the United States Pharmacopeial Convention. He served as Chair of the Modified Release Focus Group for 2011 and was subsequently elected Vice Chair of the Formulation Design and Development (FDD) Section within AAPS. The FDD Section is the largest section within that 12,000 member international association. He is regularly invited to speak at multi-national pharma, scientific symposia and workshops and other academic institutions on HME.

Claudio J. Salomon, Ph.D. - ASSOCIATE EDITOR 

Claudio J. Salomon is an associate professor of pharmaceutical technology and is the head of the Pharmacy Department at the Faculty of Biochemical and Pharmaceutical, National University of Rosario, Rosario, Argentina. He received his B.S. in pharmacy from National University of Rosario (1986) and his doctorate in chemistry at National University of Rosario (1993). He was a postdoctoral fellow at the Hebrew University of Jerusalem (Israel) from 1993 to 1997.
Salomon has belonged to the Argentinean National Council Research since 1999. His teaching responsibilities are in undergraduate and doctoral programs, as well as in Latin America-European Union exchange activities. His research interests are in the areas of pharmaceutical technology, drug delivery, and biopharmacy, with an emphasis on modified release dosage forms, microencapsulation techniques applied to drugs and microorganisms and pharmaceutical nanotechnology. In recent years, his research activities have focused on the development of novel drug delivery systems for the treatment of several neglected diseases, including Chagas´disease. He is a recipient of The Mercosur Award in Science and Technology 2012. He has published more than 35 research papers in leading international pharmaceutical and chemical journals. He serves on the editorial advisory boards of Pharmaceutical Development and Technology, Molecules and Scientia Pharmaceutica. He is the cofounder of the International Meetings on Pharmaceutical Sciences.

Chuanbin Wu, Ph.D. - ASSOCIATE EDITOR 

Chuanbin Wu is currently a professor and department chair of pharmaceutics and deputy dean in the School of Pharmaceutical Sciences at Sun Yat-sen University. Wu received his doctorate in industrial pharmaceutics from the University of Texas at Austin (1999); obtained his master’s degree from Beijing University (1992); and received his bachelor’s degree from China Pharmaceutical University (1986). He had over ten years of industrial experience in the USA serving at Johnson & Johnson, Novartis, Actavis, and Watson Nutriceuticals from senior scientist, product development manager, to R'' & '' D director. He joined Sun Yat-sen University as a faculty member in late 2005. Wu’s researches focus upon novel pharmaceutical technologies, drug delivery systems, and super-generic formulation development.
Wu has frequently been invited to give presentations for international and national conferences. He has published over 160 peer-reviewed scientific papers and has over 50 granted patents or patent applications. He also serves on the editorial advisory board of seven pharmaceutical journals and the Member of Chinese Pharmacopoeia Commission. Wu was the chair of the organizing committee of the 1st and 2nd International Symposium on Industrial Pharmacy and Clinical Pharmacy.

Meet the Editorial Advisory Board of AAPS PharmSciTech 

Meet the Editorial Advisory Board of AAPS PharmSciTech

AAPS PharmSciTech is published under the leadership of a team of dedicated scientists. We invite you to meet the Editors by reading their biographical portraits below.

Gavin Andrews, Ph.D. 

Gavin Andrews (principal investigator) holds a personal chair in pharmaceutical engineering at the School of Pharmacy, Queen’s University, Belfast. His primary research interests are centered on the implementation of novel engineering approaches to the design and manufacture of drug delivery systems. His current work involves melt extrusion, injection moulding, and additive manufacturing of drug delivery systems, coupling engineering technologies with fundamental pharmaceutical science to manufacture innovative oral dosage forms and biomaterials.

Abdul Basit, Ph.D. 

Abdul Basit holds the position of professor of pharmaceutics at the University College London School of Pharmacy. He is also a visiting professor in the Faculty of Chemical and Pharmaceutical Sciences at the University of Chile. Furthermore, he holds an Honorary Research Fellow in Gastroenterology at the Wingate Institute of Neurogastroenterology, Queen Mary College, University of London.
Basit is a pharmacist by education and received his doctorate in pharmaceutics from the School of Pharmacy, University of London, in 1999. Basit’s research sits at the interface between pharmaceutical science and gastroenterology, forging links between basic science and clinical outcomes. He leads a large and multi-disciplinary research group, and the goal of his work is to further the understanding of gastrointestinal physiology by fundamental research. So far, this knowledge has been translated into the design of new technologies and improved disease treatments, many of which are currently in late stage clinical trials.
Basit is the recipient of the Young Investigator Award in Pharmaceutics and Pharmaceutical Technology from the American Association of Pharmaceutical Scientists. He also received the 2014 Academy of Pharmaceutical Sciences award. Moreover, he is the founder and director of a number of companies including FabRx and Intract Pharma. Basit also serves on the scientific advisory boards of pharmaceutical companies, healthcare organizations, and charitable bodies.

Prakash Bhagav, Ph.D 

P_Photo_PRAKASH BHAGAV_120x150px
Prakash Bhagav, Ph.D., is currently a Reviewer in the Division of Bioequivalence, Office of Generic Drugs at U.S Food and Drug Administration (FDA) at Silver Spring, MD. Prior to joining FDA, he was Postdoctoral Research Associate at the Department of Pharmaceutics and Drug Delivery, University of Mississippi, Oxford, Mississippi.
Prakash received his Ph.D in Pharmaceutics from Birla Institute of Technology and Science (BITS), Pilani, India and M. Pharm and B. Pharm from RGUHS, Bangalore, India.
He has about six years of industrial research experience working on new and generic drug product development for oral and ophthalmic products, in vitro and in vivo evaluation, especially for glaucoma and uveitis. His research interest includes pre-formulation, formulation development, pharmacokinetic and pharmacodynamic evaluation of oral and ophthalmic drug delivery systems. He has authored/coauthored 09 research papers and 02 book chapters and has more than 25 scientific presentations at national and international conferences. He is a recipient of UGC Research fellowship during his Ph.D and GATE fellowship from MHRD, India during his M.Pharm.
He is currently a peer-reviewer for 09 reputed pharmaceutical journals and has recently joined AAPS PharmSciTech as an editorial advisory board member.

Robin Bogner, Ph.D. 

Bogner, author
Robin Bogner, Ph.D., is an associate professor of pharmaceutics in the Department of Pharmaceutical Science at the University of Connecticut where she is also a member of the Institute of Materials Science and a University Teaching Fellow. She received her Bachelor of Science in pharmacy from Rutgers University; her Master of Science from the University of Iowa; and her doctorate from Rutgers University, after which she joined the faculty at the University of Connecticut.
Bogner’s research interests are focused on solid dosage forms, both oral solids and parenteral lyophilized solids. In the area of oral solids, her work has involved the characterization of the microenvironment near the surface of dissolving excipients, demonstrating that the microenvironment differs significantly from the bulk fluid, not only in its pH but also its dielectric constant and viscosity, which have significant impact on the dissolution of all compounds in that microenvironment.
Her patented dissolution flow-cell is currently in use at four pharmaceutical companies. Bogner’s group has explored mesoporous silicates and amorphous solids to enhance dissolution of poorly soluble compounds. Solution mediated phase transformations of highly soluble solid forms to their less solubility forms is one focus area of her research. She has recently extended her dissolution expertise to address the unacceptably long reconstitution times of highly concentrated lyophilized protein therapeutics.
Bogner has served on the U.S. Pharmacopeial Convention’s Expert Committee and held various leadership positions at the American Association of Pharmaceutical Scientists and the America Association of Colleges of Pharmacy.

Francesca Buttini, Ph.D. 

Francesca Buttini
Francesca Buttini currently holds an assistant professor position at the Department of Pharmacy, University of Parma, in the group of Professor Paolo Colombo and Professor Ruggero Bettini. Since October 2014, she has also been a visiting lecturer at the Institute of Pharmaceutical Science of King’s College, London.
In 2003, she obtained an M.Sc. in Pharmacy from the School of Pharmacy of the University of Parma, and in 2007 she received a Ph.D. in biopharmaceutics-pharmacokinetics defending a thesis on “Dry powder inhaler combined formulations for the treatment of asthma and COPD.” In 2008, the European Socrates Programme and Chiesi Farmaceutici S.p.a. supported her postdoc research period at the King’s College London under the supervision of Professor Christopher Marriott.
Buttini works on the development of innovative pulmonary products such as solutions for nebulisation and metered dose inhalers, but her main research area is the formulation of dry powder inhalers. She is an expert on particle engineering, dissolution testing of microparticles, and characterization of carrier-based formulations. She has edited of a specialist scientific book on pulmonary drug delivery and published 4 patents and 25 original research papers.
Finally, in 2013 Buttini, with three colleagues of University of Parma, founded PlumeStars Srl, an innovative start-up focused on the development of antibiotic powders for inhalation.

Stephen R. Byrn, Ph.D. 

Stephen R. Byrn is Charles B. Jordan Professor at the School of Pharmacy, Purdue University and also Head of the Department of Industrial and Physical Pharmacy. His research focuses on the solid-state chemistry of drugs and has emphasized the application new instrumental techniques to pharmaceutical problems.
He is a member of the USP Council of Experts and past chair of the FDA pharmaceutical sciences advisory committee. He is also extensively involved in stability studies of solids. Professor Byrn has broad experience as a consultant in the pharmaceutical industry and is one of the founders of SSCI.

Carla M. Caramella, Ph.D. 

Carla M. Caramella is professor of Pharmaceutical Technology and Biopharmacy at the Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Pavia, Italy. She received her Doctrate in Chemistry and Pharmaceutical Technology from the University of Pavia. Her teaching responsibilities are in undergraduate and PhD programmes, as well as in continuing education and European Union exchange activities.
Professor Caramella’s current research interests are in the design and evaluation of delivery systems and include: mucoadhesive gels for buccal and vaginal antiviral treatment, prolonged release oral dosage forms based on anionic polymer-basic drug interaction products, films for ocular therapy, mucoadhesive spray solutions for mucositic treatment, characterization of new chitosan derivatives. She has more than 160 publications, including journal and conference papers, and is co-inventor of six patents.
She currently supervises the research projects of PhD students, post-docs and visiting faculty. Professor Caramella serves on the Editorial Boards of S.T.P. Pharma Sciences, Pharmaceutical Development and Technology, Pharmaceutical Technology Europe and Bollettino Chimico Farmaceutico. She also serves as an expert appointed by the Italian Ministry of Health for the European Pharmacopea and for EMEA.

Mahavir B. Chougule, Ph.D. 

Mahavir Chougule, Editor
Biography: Dr. Mahavir B. Chougule, is an Assistant Professor of the Department of Pharmaceutical Sciences, College of Pharmacy, University of Hawaii at Hilo. Chougule's research is focused on development of therapeutic agent and siRNA based nanoparticle systems for the treatment of cancer and pulmonary disorders. In addition, he has experience in area of inhalation, topical and transdermal drug delivery. He has 6 years of postdoctoral research experiences and two years of Industrial research experience.
Dr. Chougule has 15 publications, 8 filed patents, 2 review article, one book chapter, and 45 scientific presentations to his credit. Dr. Chougule is serving as member of editorial board and reviewer for pharmaceutical sciences journal. He is an active member of American Association of Pharmaceutical Scientist and American Association of Cancer Research. Dr. Chougule is a recipient of several national and international awards including recent American 2011 Association of Cancer Research Minority-Serving Institution Faculty Scholar in Cancer Research Award, USA.
Research Interest: gene therapy, chemotherapy, nanotechnology based novel delivery systems, lung and breast cancer, asthma, molecular biology, tumor models,

Gaia Colombo, Ph.D. 

Gaia Colombo was born in Italy in 1976. In 2001 she graduated in pharmaceutical chemistry and technology from the University of Parma, Italy, after an eight-month research internship at the Faculty of Pharmacy, University of South Paris XI, France. From 2002 to 2004 she was granted a Ph.D. scholarship from the University of Parma, allowing her to be appointed for 18 months at the Massachusetts Institute of Technology, USA, in Robert Langer’s group, where she worked on drug delivery systems for prolonged local anesthesia. Since January 2004, she is permanently appointed as assistant professor by the School of Pharmacy, University of Ferrara (Italy). She teaches “Pharmaceutical Technology” for the undergraduate pharmacy program.
Colombo’s research focuses mainly on transmucosal (nasal, buccal), respiratory and oral drug delivery. In 2008 to 2010 she participated in a project funded by the CARISBO Foundation on nose-to-brain delivery of antivirals in veterinary viral encephalitis. She is principal investigator of the project “FIRB 2010” funded by the Italian Ministry of Research, University and Education. Another ongoing project funded by the Emilia-Romagna Region is on in vitro methods for antiviral drug assessment.
Colombo has published 40 scientific papers, 8 proceedings, as well as 4 patents and 5 book chapters. She has been invited as lecturer by several academic and nonacademic institutions in Italy, France, Spain, Switzerland, Canada, Turkey, and Australia. In 2006, she founded the AAPS Italian University Network Student Chapter, the first European chapter of the American Association of Pharmaceutical Scientists (AAPS), for which she served as chair in 2006 to 2007.

Paolo Colombo, Ph.D. 

Paolo Colombo is Professor and Head of the Pharmaceutical Department at the University of Parma, Italy. He received his Doctorate in Pharmacy from the University of Pavia in 1968 and following a Fellowship, joined the Faculty of Pharmacy at Pavia in 1971. In 1986 he joined the Faculty of Pharmacy at the University of Parma.
He has published 162 papers in the scientific literature and has filed 30 patents on pharmaceutical products. Professor Colombo is the recipient of numerous awards and honors including the Colorcon Award (1991), AAPS Fellow (1996), Outstanding Paper in J. Controlled Release (1999) and was an invited Professor at University Paris-Sud (2001).
He serves on numerous editorial boards including European Journal of Pharmaceutical Sciences, Journal Controlled Release, Pharmaceutical Research, Pharmaceutical Technology and STP Pharma Sciences. Professor Colombo is a member of FIP, EUFEPS, AAPS and APGI.

Linda A. Felton, Ph.D. 

Linda A. Felton is a professor of pharmaceutics and chair of the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of New Mexico. She earned a B.S. in pharmacy (1986) and a Ph.D. in pharmaceutics (1997) from the University of Texas at Austin. Her research interests are focused on polymeric film coating and modified release drug delivery systems.
She has presented her work at national and international conferences, published extensively in peer-reviewed journals, and serves as peer reviewer for a number of scientific journals. Felton is the manufacturing section editor of the 22nd edition of Remington: The Science and Practice of Pharmacy, the coeditor of the 3rd edition of Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms, and editor of Remington: Essentials of Pharmaceutics. She has authored or coauthored 15 book chapters.
Felton has a joint appointment with the Department of Veteran’s Affairs Cooperative Studies Program where she oversees the formulation development of clinical trials materials. She is a current member of the American Association of Pharmaceutical Scientists, the Controlled Release Society, and the International Society for Pharmaceutical Engineering.

Paul W.S. Heng, Ph.D. 

Paul W.S. Heng has a basic degree in pharmacy and obtained his doctorate from the National University of Singapore in 1985. He has since joined the National University of Singapore as a faculty member, currently serving as an associate professor with the Department of Pharmacy. He served as head of department for two terms from 2000 to 2004 and is the principal investigator for GEA-NUS Pharmaceutical Processing Research Laboratory, a research laboratory focused in process and product development related to pharmaceutical technology.
Heng was a founding member and past president of the Asian Association of Schools of Pharmacy and also served in the formation of the Asian Federation of Pharmaceutical Scientists. He has an adjunct appointment with the Institute of Chemical and Engineering Sciences, an A*STAR institute, and is currently the chairman of the Quality Control Advisory Committee, Ministry of Health, Singapore, and vice-chairperson of the Specialty Committee of TCM Pharmaceutics of World Federation of Chinese Medicine Societies, among others. His research interest is in pharmaceutical technology, in areas of coating, pelletization, microencapsulation, powder technology, preparation of botanicals, controlled release formulations, and process science. He has authored or coauthored over 220 international refereed research journal articles, a number of conference and other non-refereed papers, and seven book chapters.

Anthony J. Hickey, Ph.D. 

Anthony Hickey is Professor of Drug Delivery and Disposition and Biomedical Engineering and Mathematics at the University of North Carolina in Chapel Hill. He obtained a Ph.D. in Pharmaceutical Sciences from the University of Aston in Birmingham (1984). Prior to his joining the University of North Carolina, Dr. Hickey held postdoctoral positions, at the University of Kentucky (1984-1988) and a faculty appointment at the University of Illinois at Chicago.
Dr. Hickey supervises a multidisciplinary group of biomedical engineers and pharmaceutical scientists studying aerosol drug delivery to, disposition in, and from the lungs. His research focuses on novel approaches to the treatment of lung diseases.
He has published over a hundred papers and chapters in the pharmaceutical and biomedical literature and has edited two texts on the subject of pharmaceutical inhalation aerosols. In 1990 he received the Young Investigator Award in Pharmaceutics and Pharmaceutical Technology from the American Association of Pharmaceutical Scientists. In 2000 he was elected a Fellow of the Institute of Biology of the United Kingdom.
He is President and CEO of Cirrus Pharmaceuticals, Inc., founder of Oriel Therapeutics, Inc., a member of the scientific advisory board of several companies and of the editorial advisory boards of Critical Reviews in Drug Carrier Systems, The AAPS Journal., AAPS PharmSciTech, Pharmaceutical Technology, Pharmaceutical Research, Pharmaceutical Development and Technology and Particulate Science and Technology.

Mansoor A. Khan, Ph.D. 

Mansoor A. Khan is the director of Product Quality Research and a senior biomedical research scientist (SBRS) at the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA), where he leads research teams on biotech products, chemistry and stability, drug delivery systems, and bioavailability/bioequivalence. Prior to joining FDA in 2004, he was a professor of pharmaceutics and director of the graduate program in the School of Pharmacy at Texas Tech University Health Science.
Khan is a registered pharmacist and earned his doctorate in industrial pharmacy from the St. John's University School of Pharmacy in 1992. He has published over 255 peer-reviewed manuscripts, four texts including Pharmaceutical and Clinical Calculations, 25 book chapters, 200 poster presentations, and more than 175 invited presentations worldwide.
He has held several leadership positions at the American Association of Pharmaceutical Scientists, including chair of the former Pharmaceutics and Drug Delivery section and founding chair of the Formulations Design and Development section. He serves on the editorial board of Pharmaceutical Technology, the International Journal of Pharmaceutics, AAPS PharmsciTech, and Drug Delivery and Translational Research. He received the AAPS Research Achievement Award in Formulations Design and Development in 2012 and is an AAPS Fellow.

Peter Kleinebudde, Ph.D. 

Peter Kleinebudde is a pharmacist and finished his dissertation at the University Kiel in 1987. He then spent some years at Glaxo GmbH, Germany, in Pharmaceutical Development and Bulk Production. In 1997, he received the German “Habilitation” about work on pellets. During a stay at the Royal Danish School of Pharmacy in Copenhagen, he was appointed as associate professor at the University Halle-Wittenberg in 1998. From 2002 to 2003, he was dean of the School of Pharmacy. In 2003, Peter was nominated as full professor at the Heinrich-Heine-University Duesseldorf. Since 2011, he has been the chair of the Department of Pharmacy and member of the academic senate of the University.
Peter is a member of several scientific societies including the American Association of Pharmaceutical Scientists, International Association for Pharmaceutical Technology (APV), Dechema, and VDI. He was president of the APV from 2002 to 2010 and since then he is head of the APV focus group Solid Dosage Forms. He is a member of the editorial boards of the European Journal of Pharmaceutics and Biopharmaceutics, AAPS PharmSciTech, the Journal of Pharmaceutical Science, and Pharmaceutical Development and Technology. He is chair of the Powder Working Party and member of Group 12 of the European Pharmacopoeia. In 2004, he was appointed as AAPS Fellow. In 2013, he received the Dr. honoris causa degree from the University of Szeged (Hungary).
His main research interests are solid dosage forms and pharmaceutical processes, including roll compaction / dry granulation, extrusion, and coating. He has published more than 160 peer-reviewed papers, 300 abstracts and conference proceedings, and has given more than 200 invited lectures.

Ping Ma, Ph.D. 

Ping Ma is currently a scientist in Global Pharmaceutical Research and Development at Hospira Inc. He works on preformulation and formulation development, manufacturing process optimization, analytical method validation, process validation, and technology transfer of sterile injectable products for Hospira and/or third party customers. Ma has more than 10 years of pioneering research experience in various drug delivery systems from oral to parenteral.
Ma has authored or coauthored of over 20 scientific articles in the area of formulation development and drug delivery, and more than 30 scientific presentations at national and international conferences. In addition, Ma serves on editorial advisory board for several drug delivery and pharmaceutical science journals and has been a peer reviewer for more than 10 scientific journals.
He received his doctorate in drug delivery from the University of North Carolina at Chapel Hill, with his dissertation focused on the development of lipid-based nanoparticle formulations for improved cancer treatment. Prior to that, Ma received his B.S. in drug delivery from China Pharmaceutical University and M.S. in drug delivery from the University of Toledo, Ohio.

Prashanth Manda, Ph.D. 

Prashanth Manda
Prashanth Manda, Ph.D., is a visiting associate in the Division of Bioequivalence at the Food and Drug Administration in Silver Spring, Md. He received his bachelor’s in pharmacy from Kakatiya University, Warangal, India, and his doctorate in pharmaceutics from the University of Mississippi, Oxford, Mississippi, in 2014. His research interest includes preformulation, formulation, and kinetics of oral, nasal, sublingual, transungual, topical, and transdermal drug delivery systems. He is author/coauthor of 10 original research publications and a book chapter. He is a recipient of predoctoral fellowship from the National Institutes of Health, Center of Research Excellence in Natural Products Neuroscience in 2010. He is a member of national honor societies like Sigma Xi, Phi-Kappa-Phi, and Rho-Chi.
Manda is currently serving as an official reviewer for several journals in the field of pharmaceutical sciences which are well renowned and has recently joined the journal AAPS PharmSciTech as an editorial advisory board member.

Dave A. Miller, Ph.D. 

Dave A. Miller serves as the vice president of research and development at DisperSol Technologies, LLC. Prior to joining DisperSol, Miller held the position of senior principal scientist in the Pharmaceutical and Analytical Research and Development Department at Hoffmann-La Roche, Inc., in Nutley, New Jersey. Miller earned his B.S. in chemical engineering and his doctorate in pharmaceutics from the University of Texas at Austin.
Miller specializes in formulation and processing technologies for improving oral absorption of insoluble small molecules. He has applied his expertise toward advancing numerous drug candidates in various stages of development from discovery support through to phase 3 clinical studies. Specifically, his expertise includes: amorphous formulation technologies, solid dispersion technologies, solubility enhancement, KinetiSol dispersing, hot-melt extrusion, spray drying, particle engineering technologies, non-sink dissolution testing methodologies, establishing in vitro-in vivo relationships, solid state characterization, physical stability assessment of amorphous systems, and final dosage form design.
Miller has published numerous highly-cited peer-reviewed research articles, authored several book chapters, is an inventor on several granted and pending patents, and is a coeditor of the recently published book, Formulating Poorly Water-Soluble Drugs.

Viness Pillay, Ph.D. 

Pillay, author
Viness Pillay, Ph.D., is a Fulbright Scholar and Fellow of the African Academy of Sciences. He is a South African NRF Tier 1 Research Chair in Pharmaceutical Biomaterials and Polymer-Engineered Drug Delivery Technologies at the University of the Witwatersrand, Johannesburg, South Africa. He is also a personal full professor of pharmaceutics and head of pharmaceutics and pharmaceutics research in the Department of Pharmacy and Pharmacology.
Pillay is the director of the Wits Advanced Drug Delivery Platform, which encompasses the research, development, and eventual commercialization of innovative drug delivery systems currently under development by his research team. He is also the director of the African Network for Drugs and Diagnostics, Center of Excellence in “Advanced Drug Delivery Technology.” In addition, he is designated as the institutional director of the Wits Hub of the National Medical Devices Innovation Platform, an initiative of the Medical Research Council, Innovation Center of South Africa.
Pillay currently supervises the largest cohort of graduate students in the pharmaceutical sciences in South Africa. He also serves as a reviewer, editorial board member, and lead guest editor of international scientific journals and books. Further information may be obtained at http://www.wits.ac.za/waddp.

Javier O. Morales, Ph.D. 

Javier O. Morales is an assistant professor in the Department of Pharmaceutical Science and Technology at the School of Chemical and Pharmaceutical Sciences of the University of Chile. He received his Bachelor of Science in pharmacy (2006) and a Professional Degree in pharmacy (2007) at the University of Chile; and he received his Ph.D. from The University of Texas at Austin (2012), after which he joined the faculty at the University of Chile.
Morales’s lines of research are directed towards the development of novel dosage forms for the delivery of peptide and protein drugs. The strategies employed for this purpose include the use of delivery systems for alternative routes of administration and nanoencapsulation of peptides and proteins for targeting and tailoring drug release. His past and current research in alternative delivery routes of administration are aimed at enabling buccal absorption of biomacromolecular drugs using nanostructured polymeric films as dosage forms. His current research in nanoparticulate delivery systems is aimed at achieving formulations for cardiovascular diseases, developing brain targeted delivery systems, as wells as establishing the fundamental variables controlling the formation of nanoparticles by coacervation.
He has published 17 research papers and book chapters, 3 patent applications, and has presented over 45 abstracts in national and international meetings and workshops. He directs 3 sponsored projects and participates in two more as an associate researcher. As an active member of the American Association of Pharmaceutical Scientists (AAPS), Morales has served in screening committees for the AAPS Annual Meeting and Exposition. Morales currently serves on the editorial advisory boards of Drug Development and Industrial Pharmacy and AAPS PharmSciTech.

S. Narasimha Murthy, Ph.D. 

S. Narasimha Murthy, Ph.D., is an associate professor of pharmaceutics and drug delivery at the University of Mississippi School of Pharmacy. His areas of research are dermal/transdermal drug delivery, drug delivery across the nail plate, and intranasal delivery of biologicals (http://www.olemiss.edu/~murthy). Murthy has published over ninety peer-reviewed research papers and edited two books on topical delivery of drugs. His research programs are funded by the National Institutes of Health (NIH), the Food and Drug Administration, and pharmaceutical companies. He is the recipient of several awards including the Global Indus Technovator award from MIT. Murthy serves on the editorial board of over fifteen journals. He is also serving as grant reviewer to the NIH and government funding agencies of Italy, UAE, Portugal, and the UK. Murthy is the founder-director of a nonprofit research facility, “Institute for Drug Delivery and Biomedical Sciences,” in Bangalore, India (www.IDBResearch.org ).

Wasfy Obeidat, Ph.D. 

Wasfy Obeidat is an associate professor at Jordan University of Science and Technology (JUST) in Irbid-Jordan, born in Irbid in 1972 with Jordanian nationality. He had his B.Sc. in pharmacy and an M.Sc. in pharmaceutical technology from Jordan University of Science and Technology in Irbid-Jordan, and a doctorate in pharmaceutics from University of Georgia, Athens, USA.
Obeidat has received awards such as the Excellent Research Project award in 2008 from the H. Hijjawee Establishment, Jordan, and the award of Best Invention in 2007 from the Philadelphia University, Jordan. He also received the Daniel Turnberg Travel Fellowship Scheme Award in 2014 and the DFG Fellowship Award, Germany, in 2008.
He has held various administrative positions such as an assistant dean at JUST (2006–2007), chair, Department of Pharmaceutical Technology, faculty of pharmacy at JUST (2011–2013), and vice dean at JUST from September 2014 through the present. He has one U.S. patent application, published a book, and has several research articles published in international journals. Obeidat attended many conferences and workshops, supervised and cosupervised master students, and served as a reviewer for several international journals.

Eun-Seok Park, Ph.D. 

Eun-Seok Park, professor of physical pharmacy at Sungkyunkwan University, received his B.S. (1981) from Sungkyunkwan University, his M.S. (1989) from University of Iowa in pharmaceutics (pharmacokinetics), and his Ph.D. (1995) from the Medical University of South Carolina in pharmaceutics (physical pharmacy).
He is the director of Drug Delivery Technologies Research Center (DRC), a DDS technologies research center in Sungkyunkwan University. He was the editor of Archives of Pharmacal Research from 2007 to 2008. He is the vice president of the Korean Society of Pharmaceutical Sciences and Technology. He is an active editorial advisory board member of AAPS PharmSciTech.

Thomas Rades, Ph.D. 

Since March 2012, Thomas Rades has been the research chair in pharmaceutical design and drug delivery in the Department of Pharmacy, University of Copenhagen. Before that, he was the chair in pharmaceutical sciences at the National School of Pharmacy, University of Otago, New Zealand, from 2003 to 2012.
In 1994, he received his doctorate from the University of Braunschweig, Germany, for his work on thermotropic and lyotropic liquid crystalline drugs. After working as a research scientist in preclinical development and formulation at F. Hoffmann-La Roche in Basel, Switzerland, he became a senior lecturer in pharmaceutical sciences at Otago in 1999 and has been the chair of pharmaceutical sciences in Otago since 2003.
Rades has developed an international reputation for his research in the physical characterization of drugs solid dosage forms as well as in vaccine delivery using nanoparticulate systems (both polymeric and lipid based). He has published more than 275 papers in international peer-reviewed journals as well as several book chapters, one book, and patents. He is an editor for the Journal of Pharmaceutical Sciences and the European Journal of Pharmaceutics and Biopharmaceutics, and an associate editor for the Journal of Pharmacy and Pharmacology. He holds an honorary doctorate of Åbo Akademie University, Finland, a visiting professorship at the Department of Medicine at the University of Adelaide, Australia, and an honorary professorship at the University of Otago, New Zealand. He is an Eminent Fellow of the Academy of Pharmaceutical Sciences (UK) and a Fellow of the New Zealand Institute of Chemistry. Rades has successfully supervised more than 50 doctorate students. For his undergraduate and postgraduate teaching, he was awarded the New Zealand Tertiary Teaching Excellence Award for Sustained Excellence (2005).
His research interests include the solid state of drugs and dosage forms and nanoparticles as delivery systems for drugs and vaccines. Research in both areas aims to improve drug therapy through appropriate formulation and characterization of medicines and to increase understanding of the physicochemical properties of drugs and medicines. It combines physical, chemical, and biological sciences and technology to optimally formulate drugs and vaccines for human and veterinary uses.

Jay Babu Ramapuram, Ph.D. 

Jay B. Ramapuram, Editor
Jay Babu Ramapuram is Associate Professor of Pharmaceutics at Harrison School of Pharmacy, Auburn University. He received his Ph.D. Degree (Pharmaceutics) in 1998 from Institute of Technology, Banaras Hindu Unviersity, India.
He worked as Assistant Manager of Product Development at GlaxoSmithKline Pharmaceuticals, India. He has taught various pharmaceutics courses to Pharm D students and has taught Tablet manufacturing, formulation of protein and peptide drugs, drug products and biopharmaceutics courses at the graduate level at Auburn University. He has served/serving as major professor for four M.S. and 4 Ph.D students.
His research interests include: topical and transdermal delivery, nanoparticle formulation and characterization, excipient characterization, formulation of solid dose products, solubility improvement of drugs. He has published over 50 peer-reviewed abstracts and 50 research articles.
Dr. Ramapuram is a Postdoctoral Fellow of the American Association of Pharmaceutical Scientists and active member of Formulation and Drug Delivery Section and serve in AAPS abstract screening committees.

Alessandra Rossi, Ph.D. 

Alessandra Rossi
Alessandra Rossi, Ph.D., graduated in chemistry from the University of Pavia (ITA) after a six-month research internship at the Department of Organic Chemistry, Faculty of Agriculture and Applied Biological Sciences, University of Gent (Gent, BEL). From 1994 to 1997, she was granted of a Ph.D. scholarship from the University of Strathclyde (Glasgow, GBR), and she carried out her Ph.D. research project in the Department of Pure and Applied Chemistry. She received her Ph.D. from the University of Strathclyde in 1998.
Also in 1998, she received a Postdoc Research Fellowship from Novartis (Basilea, CHE) at Heriot-Watt University, Department of Mechanical and Chemical Engineering (Edinburgh, GBR).
Since November 1999, she is permanently appointed as assistant professor at the School of Pharmacy, University of Parma (ITA). In February 2004, she was a visiting professor in Socrates/Erasmus European Programme at Department of Pharmacy and Pharmacology, University of Bath (GBR), and she was a visiting professor in Socrates/Erasmus European Programme at Department of Pharmaceutical Technology, University of Ankara (TUR), in September 2008. Moreover, both in 2010 and 2011 she was appointed for a month as an invited professor at Faculty of Pharmacy, University of Claude Bernard Lyon 1 (FRA).
Her research interests mainly focus on oral swellable matrices for drug delivery control, Dome Matrix technology for time and space drug controlled delivery, powder agglomerates, and nasal and pulmonary delivery.
She is author of more than 45 peer-reviewed scientific publications in international journals, 2 reviews, 4 patents, 2 book chapters, and several oral and poster communications to international congress.

Juergen Siepmann, Ph.D. 

Juergen Siepmann (born 1969) studied pharmacy and obtained his doctorate at the Freie Universitaet Berlin, Germany. Since 2004 he has been a professor of pharmaceutical technology at the University of Lille, France. He is heading the French National Institute of Health and Medical Research (INSERM) research group Controlled Drug Delivery Systems and Biomaterials, which is located at the College of Pharmacy, School of Medicine, and School of Dentistry. The team includes about 6 professors, 6 senior lecturers, 5 technical/administrative staff, 15 postdocs and doctorate students, and 10 master’s students.
Siepmann’s research focuses on controlled drug delivery systems, in particular on the elucidation of the underlying mass transport phenomena and the optimization of the devices. So far, he has published his work in more than 140 articles in peer-reviewed, international scientific journals, 250 poster presentations, and 100 oral presentations at national and international scientific meetings. He is the editor of 3 books, author of 16 book chapters, and inventor of 10 patents.
Siepmann’s awards include the 2012 APV Research Award for Outstanding Achievements in the Pharmaceutical Sciences, a Marie Curie Individual Post-Doctoral Fellowship, and the APV-Prize for the outstanding doctoral thesis in pharmaceutical sciences from the years 1998/99. He acts as the reviews editor for the International Journal of Pharmaceutics, coeditor for the Journal of Drug Delivery Sciences and Technology, and is a member of several editorial boards. Since 2010, Siepmann has served as president of the International Society of Drug Delivery Sciences and Technology (APGI, www.apgi.org).

Eryvaldo Sócrates Tabosa do Egito, Ph. D. 

Para OLattes, Editor
Professor E. Socrates Egito received his doctoral degree in Pharmacy from the Université de Paris (Paris-Sud) in 1994. He was a pos-doc fellow at the University of Georgia, from 2001 to 2001 and actually is a Visitor Professor at the University of Florida since 2011, USA. Currently, he is Full Professor at the Universidade Federal do Rio Grande do Norte and a Researcher CNPq Fellow since 2008. He has published 72 papers in scientific journals and authored 366 presentations at national and international scientific meetings.
He has advised 15 Master of Sciences and 13 Ph. D. students. He has received 7 awards/honors and coordinated 9 sponsored research projects and several not sponsored ones. In his professional activity, he has interacted with 110 collaborators, who were co-authors in scientific works. He also has been act as a consulting for Pharmaceutical Industries and Federal Agencies of Education. His scientific studies focus mainly on pharmaceutical technology, pharmaceutical industry and pharmaceutical nanotechnology. His scientific production is focused in nanotechnology, amphotericin B, microparticles, emulsions, xylan, stability, spontaneous emulsification and HLB.

Wei Wu, Ph.D. 

Wei Wu, professor of pharmaceutics at Fudan University School of Pharmacy, received his B.S. (1992) and M.S. (1996) from the Second Military Medical University, China, and his Ph.D. (1999) from West China University of Medical Sciences, China. He joined Fudan University School of Pharmacy as a faculty member in 2000. He previously served his school as a vice dean and vice director for the Institute of Pharmacy (2007–2012).
His current research interests are focused on oral drug delivery systems with emphasis on enhancing the oral bioavailability of poorly water-soluble drugs and biomacromolecules using nanoscale delivery carriers. One of his ongoing missions is to elucidate the in vivo fate and mechanisms of lipid-based nanocarriers. He also has a keen interest in pharmaceutical technologies, especially those involved in solidification of formulations of liquid origin.
His awards include the New Century Excellent Teachers of Ministry of Education Shanghai Twilight Scholar, Shanghai Excellent Young Teachers of Universities, Young Pharmaceutical Scientist by the Chinese Pharmaceutical Association, etc. He is now an expert committee member for drug evaluation for the State Food and Drug Administration, for drug pricing for the National Development and Reform Committee, and for veterinary medicines for the Ministry of Agriculture.
He serves in editorial advisory board of over ten professional journals. He has published over 150 peer-reviewed articles in the field of pharmaceutics and nanomedicine.

Paul Young, Ph.D. 

Young is the head of respiratory technology at the Woolcock Institute of Medical Research; associate professor at the Sydney Medical School, University of Sydney; an Australian Research Council Future Fellow; and an honorary adjunct professor at the University of Technology Sydney. He has made a significant contribution in the field of advanced drug delivery and inhalation science. Young has published more than140 peer-reviewed international journal articles (>2000 citations), 5 patents, 13 book chapters, and in excess of 100 conference proceedings. He has an H-index of 26 and 5-year i10 index of 70. In addition, he has given invited conference seminars on multiple occasions and has been on the organizing committees for international science conferences.
Young has been appointed onto the Australian Research Council College, the external TGA medical advisory committee, and the editorial board of a range of journals including Pharmaceutical Research, Journal of Pharmacy and Pharmacology, Drug Development and Industrial Pharmacy, Inhalation magazine, and Respiratory Drug Delivery. He was a founding director of Nanopharm Ltd in the U.K. and is director of Pulmatix Pty Ltd in Australia, a specialist contract drug development and testing company. Young collaborates with both academia and industry on an international level and has attracted more than 10 million dollars AUD in funding within the area of inhalation medicine.

Melgardt M. De Villiers, Ph.D. 

Melgardt M. De Villiers
Melgardt M. De Villiers is currently an associate professor at the University of Wisconsin School of Pharmacy. He earned a B.Pharm. in pharmacy, M.Sc. and Ph.D. in pharmaceutics, and also a D.T.E. degree in higher education all from North-West University, South Africa, and completed his postdoc in pharmaceutics from the University of Iowa, College of Pharmacy, working with Professor Dale Eric Wurster. His past professional experience includes adjunct professor at the School of Pharmacy, North-West University, South Africa; associate professor in the Division of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, USA; and the Department of Pharmaceutics, North-West University, South Africa.
His current research is focused on determining the pharmaceutical science involved in developing an understanding of the pharmaceutics, engineering, and materials sciences principles underlying enhanced drug delivery technologies. Several of his publications have been related to layer-by-layer nanocoating and to solid-state properties of drugs and excipients. De Villiers is a recipient of the Outstanding Professor in the College of Health Sciences at the University of Louisiana at Monroe.

James C. (Jim) DiNunzio, Ph.D. 

James DiNunzio
James DiNunzio received his Ph.D. in pharmacy (pharmaceutics) at The University of Texas and is currently a principal scientist at Merck & Co., Inc., in Kenilworth, New Jersey, where he heads the Hot-Melt Extrusion Technology Development Team. He also holds master’s and bachelor’s degrees in chemical engineering from Columbia University and SUNY Buffalo, respectively. Prior to his position at Merck, he held roles of increasing responsibility at Roche, PharmaForm, and Forest Laboratories. He currently serves as a member of the AAPS PharmSciTech Editorial Advisory Board and scientific advisor to the editors for the Journal of Pharmaceutical Sciences. He has authored numerous research papers in the field of hot-melt extrusion and formulation design for bioavailability enhancement. His current research interests include: formulation design for bioavailability enhancement, melt extrusion process design for challenging systems, and the development of continuous manufacturing technologies.

Alf Lamprecht, Ph.D. 

Alf Lamprecht
Alf Lamprecht obtained his Pharm.D. and Ph.D. degrees from Saarland University, Germany. After postdoctoral training in France and Japan, he was appointed as an assistant professor at the University of Nancy, France, before becoming a professor of pharmaceutical engineering at the University of Franche-Comté in Besançon, France, in 2005. He is currently a professor of pharmaceutics at the University of Bonn, Germany, where he is serving as the head of the School of Pharmacy. He is an Alexander-von-Humboldt Fellow and was nominated as a member of “Institut Universitaire de France” in 2007. His research deals with particulate systems for drug delivery with a special focus on the design of nanoscale drug carriers for drug delivery across absorption barriers and drug delivery towards inflamed tissues.

Stuart C. Porter, Ph.D. 

Stuart Porter
Stuart Porter is currently a senior research fellow with responsibility for Global Film-Coating Technology at Ashland Specialty Ingredients (ASI). Prior to joining ASI, for over 25 years Porter had extensive technical experience with Colorcon and was responsible for leading the development of a broad range of coating systems for which that company is well recognized, following which he was a consultant to the global pharmaceutical industry, specializing in providing services relating to oral drug delivery.
Porter is a globally recognized leader in tablet-coating technology, with over 35 years of experience with film-coating applications, the design of immediate- and modified-release coating products, unit operations associated with the preparation of oral solid dosage forms, and oral drug delivery; his recent interests have expanded into continuous processing as it relates to the manufacture of oral solid dosage forms.
He has published and presented widely on coating technology and holds eight patents related to coating systems. Porter is a member of the Royal Pharmaceutical Society of Great Britain, the American Association of Pharmaceutical Scientists, and the American Pharmacists Association.

Tansel Comoglu, Ph.D. 

Tansel  Comoglu
Tansel Comoglu graduated from Ankara University Faculty of Pharmacy in 1991. She received her M.Sc. degree in pharmaceutical technology and obtained her Ph.D. in 2002 on the “Development and in-vitro in-vivo investigations of ketoprofen loaded microsponge modified release tablet formulations.” Comoglu worked as an assistant professor in 2010 and received her associate professor title in 2011. She was awarded postdoctoral research support by The Scientific and Technological Council of Turkey (TUBITAK) and continued her work at Tromso University, Institute of Pharmacy, Department of Pharmaceutics and Biopharmaceutics, Norway, on “physics of tabletting” in 2005. In 2012, she was awarded by The Council of Higher Education’s Scholarship of Turkey and studied on “Preparation and in vitro characterization of temsirolimus loaded sterically stabilized micelles (T-SSM) as a potential nanomedicine for renal cell carcinoma (RCC)” at the University of Illinois at Chicago, Department of Pharmaceutics, Bioengineering and Biopharmaceutical Sciences, College of Pharmacy, USA. She is currently continuing her research work at the Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University.
Comoglu has served as an editorial board member of Pharmaceutical Development and Technology since 2012 and the Journal of Acute Diseases starting in 2015. She is the writer of 26 scientific articles and 3 international book chapters. Comoglu has given several invited lectures and oral and poster presentations. She was awarded the Novartis Project Award in 2008 for her work on “Formulation and in-vitro evaluation of diclofenac potassium fast disintegrating tablets and their clinical application in migraine patients.”
Her current research interests include nanoparticles in cancer therapy and fast disintegrating tablets for oral use. She also serves as the Erasmus Coordinator of Faculty of Pharmacy at Ankara University since January 2012.

Ali Nokhodchi 

Ali obtained his pharmacy degree (PharmD) in 1989 from Tabriz School of Pharmacy, Iran. He completed his PhD in Pharmaceutical Technology at John Moores University, Liverpool in 1996 and has been a qualified pharmacist since 1989.He held a lectureship (1997 - 2001), and senior lectureship (2001 - 2003) at the School of Pharmacy, Tabriz University of Medical Sciences. During this period he was head of postgraduate studies and also vice-dean for research for a period of 4 years in Tabriz School of Pharmacy. In 2003 he was appointed as lecturer of pharmaceutics at King’s College London, Department of Pharmacy. He worked as a professor of Pharmaceutical Technology at Tabriz School of Pharmacy prior to this appointment as senior lecturer of Pharmaceutics at Medway School of Pharmacy, University of Kent. Ali has been promoted to Reader in 2013 and now he is a Professor and Chair in Pharmaceutics and Drug Delivery at The University of Sussex, School of Life Sciences. He has supervised over 120 Mpharm, PharmD, MSc project students and 15 PhD postgraduate students at several institutions in various fields of pharmaceutical technology. At the present, he is working on particle engineering for oral and pulmonary drug delivery, dissolution enhancement techniques and controlled release formulations. He is a regular reviewer for many international pharmacy journals and the editorial board of several journals in pharmaceutical sciences. Ali has published a significant number of manuscripts (over 200 research articles in peer-reviewed international pharmacy journals ) on various fields of pharmaceutics, mainly, tabletting, particle engineering, inhalation, continuous manufacturing, nanoparticles/nanocrystals, Transdermal delivery and controlled-release formulations. In addition, he published 5 book chapters (2010-2015) and a book on pulmonary drug delivery. He has an H-index of 36 with over 4000 citations till January 2017. His name appeared within top 1% scientists in the field of pharmacology and pharmacy discipline since 2012 published by ESI (Essential Science Indicators is part of Web of Science).

António J. Almeida, Ph.D. 

António J. Almeida is professor of Pharmaceutical Technology at the University of Lisbon, Faculty of Pharmacy, Portugal, where he is a member of the Research Institute for Medicines (iMed.ULisboa), serving as head of the Nano2B Research Group. He graduated in Pharmaceutical Sciences at the University of Lisbon (1987), obtained his PhD in pharmaceutics at the University of Aston, Birmingham, UK (1993) and received the Portuguese “Habilitation” on Pharmaceutical Sciences, at the University of Lisbon (2005). He has worked as a visiting scientist at the Freie Universitaet Berlin, Germany (1995/96), and as a visiting professor at the University of Santiago de Compostela, Faculty of Pharmacy, Spain (2012).
His main research interests involve the study of polymeric materials and solid lipids-based nanoparticles as drug carriers for overcoming biological barriers, including protein and vaccine delivery. He has authored or coauthored over 100 international refereed research papers, book chapters and 5 patents.
Since 1996 he has served as a quality expert at the National Authority of Medicines and Health Products (INFARMED, Portugal) and the European Medicines Agency (EMA). He currently serves on the editorial boards of Journal of Microencapsulation, Journal of Drug Delivery Science and Technology, and Journal of Biomedical Nanotechnology.

Feng Zhang 

Feng Zhang is an Assistant Professor of the Department of Pharmaceutics at The University of Texas at Austin. Dr. Zhang joined the academia after receiving his Ph.D. from The University of Texas College of Pharmacy and working in the pharmaceutical industry for 14 years.
His research interests include amorphous solid dispersions, abuse-deterrent dosage forms, spray drying and twin screw extrusion. Dr. Zhang's publications include over 30 peer-reviewed journal articles and book chapters, and over 30 presentations at national/international scientific meetings.

Maren Preis, Ph.D. 

Maren Preis graduated in Pharmacy and received her doctorate in Pharmaceutics and Biopharmaceutics from the Heinrich-Heine University in Düsseldorf (Germany) in 2014. Besides her PhD studies, she worked as principal scientist for Sapiotec GmbH, a contract developer for innovative drug delivery systems, and served as guest lecturer at the University of Düsseldorf from 2012 to 2015. In 2016, her PhD thesis ‘Oromucosal preparations for pharmaceutical use’ received the ‘Award for the Most Outstanding Doctoral Thesis in Pharmaceutical Sciences 2013/2014’ by the International Association for Pharmaceutical Technology (APV).
In 2015, she joined the Drug Delivery and Pharmaceutical Technology Research Group at the Faculty of Science and Engineering at Åbo Akademi University in Turku (Finland). She currently coordinates and supervises the research projects of PhD candidates, MSc students and visiting researchers.
Her research interests include pediatric drug development, personalized medicine, taste-masking strategies, oromucosal preparations (in particular orally disintegrating film formulations), and the application of inkjet and three-dimensional printing technologies for pharmaceutical use.
Dr. Preis has published 19 articles in peer-reviewed, international scientific journals, co-authored over 49 conference abstracts, and gave 10 invited lectures in national and international meetings and workshops

Zeeshan Ahmad, Ph.D 

Zeeshan Ahmad is a Professor of Pharmaceutics & Drug Delivery at De Montfort University (The Leicester School of Pharmacy). He is a Royal Society Industry Fellow (working closely with BlueFrog Design) and also leads the EPSRC EHDA Network (a highly interdisciplinary initiative involving several pharma industries and academia). He obtained his first and doctoral degrees from Queen Mary (University of London).
He has broad research interests in medical materials, their engineering and applications which are ultimately geared towards improving healthcare (interfacing at chemistry, biology, physics and biomedical engineering).Specifically, these include various modes of drug dosage form manufacturing (smart nanoparticles and microparticles, bubbles, fibrous materials, printed constructs and various barrier contact systems), tissue engineering (scaffolds and cell guidance), medical device coatings (orthopaedic implants) and biomedical material synthesis (polymers and bioceramics). He also has a very keen interest in the development of novel fabrication routes (EHDA, printing, microfluidics and electrical-centrifugal methods) to address healthcare challenges with the main emphasis on drug delivery.
He has published extensively in the field and his research has been supported by The Royal Society, EU, Leverhulme Trust, EPSRC and numerous industrial partners (from large Pharma to SME’s).

Dr. Sitaram Velaga 

P_Dr, Sitaram Velaga_95x120px
Dr. Velaga earned PhD degree in Pharmaceutics from the Department of Pharmacy, Uppsala University, Sweden in 2004. He is currently a Professor in Pharmaceutics at Luleå University of Technology Sweden and his research group is interested in the areas of pharmaceutical materials engineering and enabling formulation technologies. He has published over 70 scientific peer-reviewed articles in respected pharmaceutical journals and has delivered talks at a number of national and international conferences.
Please check http://www.ltu.se/staff/s/sitvel-1.12368?l=en for more information about Dr. Velaga’s research.

Haichen Nie, Ph.D. 

P_Haichen Nie_Photo_95x120px
Haichen Nie is a scientist in the formulation development group of Teva Branded Pharmaceutical Products R" & "D. He received his Ph.D. from the Department of Industrial and Physical Pharmacy at Purdue. During 2015- 2016, he worked in the Preformulation group of Merck Sharp " & " Dohme as a visiting scientist, focusing on the study of salt formation and disproportionation and development of innovative Raman mapping method to detect the existence of low-level analytes in drug products. He has an extensive research experience in small molecule preformulation and formulation, including amorphous solid dispersion, salt disproportionation, polymorphism, molecular interactions, and spectroscopic analysis. Dr. Nie has published a number of original research articles in these areas and has given numerous presentations at national scientific meetings. He is specialized in developing formulations, processes, and noval dosage forms for drug delivery under the constraints of the physicochemical properties of the active pharmaceutical ingredient and regulatory requirements. His overall objective is to apply knowledge of science and engineering to develop innovative research ideas in the area of drug development while continuously challenging his personal best.

Harsh Chauhan, Ph.D 

P_Harsh Pic_95x120px
Harsh Chauhan, Ph.D., is an associate professor of pharmaceutics in the Department of Pharmacy Science at Creighton University. He received his Bachelor of Pharmacy from Meerut University, UP, India and Doctorate from MCPHS University, Boston, MA. Dr. Chauhan’s research interests are in designing novel drug delivery systems such as amorphous binary and ternary solid dispersion, lipid and polymer based nanoparticles for poorly soluble drugs/ phytochemicals. He had published more than twenty-five peer reviewed article, several book chapters and presented around 40 posters in national and international conferences. He is a Selected Fellow, 2017-2018 Class, Professional Mentoring Skills Enhancing Diversity (PROMISED) Program, University of Pittsburgh, serves as faculty advisor of AAPS Creighton Student Chapter, part of steering committees of AAPS API and Targeted drug delivery focus groups. He serves as reviewer and editorial board in many reputed pharmacy journals. He is a member of American Association of Pharmaceutical Scientist (AAPS) and American Chemical Society (ACS).

For authors and editors

  • Journal Citation Reports®
    2016 Impact Factor
  • 2.451
  • Aims and Scope

    Aims and Scope


    AAPS PharmSciTech is a peer-reviewed, online-only journal committed to serving those pharmaceutical scientists and engineers interested in the research, development, and evaluation of pharmaceutical dosage forms and delivery systems, including drugs derived from biotechnology and the manufacturing science pertaining to the commercialization of such dosage forms. Because of its electronic nature, AAPS PharmSciTech aspires to utilize evolving electronic technology to enable faster and diverse mechanisms of information delivery to its readership. Submission of uninvited expert reviews and research articles are welcomed.   


    AAPS PharmSciTech publishes six issues a year. 

  • Submit Online
  • Open Choice - Your Way to Open Access
  • Instructions for Authors (pdf, 590 kB)
  • Editor Handbook (pdf, 547 kB)

Services for the Journal